
样式: 排序: IF: - GO 导出 标记为已读
-
How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-18 Carlo Gabriele Tocchetti, Arantxa González, Johannes Backs, Piero Pollesello, Peter P. Rainer, Gabriele Giacomo Schiattarella, Milena Bellin, Glenn Begley, Ildiko Bock Marquette, Jean-Luc Balligand, Ines Falcao-Pires, Rick Gorczynski, Emilio Hirsch, Jean-Sebastian Hulot, Bert Klebl, Alexander R. Lyon, Christoph Maack, Tim McKinsey, Oliver J. Müller, Ida Lunde, Rusty Montgomery, Giuseppe Vergaro, Antoni
-
The European heart failure management resources, treatment reimbursement and activities of professional and patient organizations Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-17 Petar M. Seferović, Marija Polovina, Gianluigi Savarese, Ivan Milinković, Lars Lund, Ovidiu Chioncel, Magdy Abdelhamid, Yuri Lopatin, Stefan Störk, Manuel Anguita Sanchez, Massimo Piepoli, Aldo P. Maggioni, Ewa Jankowska, Antoni Bayes-Genis, Alain Cohen Solal, Arsen Ristić, Mariya Tokmakova, Mehmet Birhan Yilmaz, Hadi Skouri, Davor Miličić, Offer Amir, Amina Rakisheva, Gerasimos Filippatos, Giuseppe
The European Heart Failure (HF) Survey was developed by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) to map HF management resources, reimbursement of drugs/devices for HF treatment, and structure and activities of HF professional and patient organizations.
-
Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy – a hypothesis-generating study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-16 Julio Nunez, Anna Mollar, Mayra Vera-Aviles, Syeeda Kabir, Akshay Shah, Paolo Polzella, Michael Desborough, Ingrid Cardells, Gema Miñana, Irene del Canto, Vanessa Ferreira, Stefan Piechnik, Alicia Maceira, Samira Lakhal-Littleton
Many patients with heart failure (HF) are iron-deficient. Intravenous (IV) iron therapy improves symptoms and reduces hospitalizations for HF. Several mechanisms have been proposed, including myocardial iron repletion. However, it is unknown if serum iron markers predict the extent of this repletion. To address this question, data from two clinical studies that evaluated changes in myocardial iron
-
Letter regarding the article ‘Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-17 Jiaying Ding, Jun Li, Yaling Li
Click on the article title to read more.
-
Cardiac resynchronization therapy for enabling guideline‐directed medical therapy optimization in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-17 Daniela Tomasoni, Lina Benson, Paolo Gatti, Alessandro Villaschi, Charlotta Ljungman, Marco Metra, Raffaele Scorza, Frieder Braunschweig, Michael Melin, Giuseppe Rosano, Michael Böhm, Javed Butler, William T. Abraham, Wilfried Mullens, Fredrik Gadler, Cecilia Linde, Lars H. Lund, Gianluigi Savarese
-
Liver stiffness measurement for non‐invasive assessment of central venous pressure in patients with heart failure: A multicentre pilot study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-16 Nicolas Girerd, Jan Biegus, Adam Janas, Piotr Buszman, Marcin Suska, Ovidiu Chioncel, Julie Foucquier, Anne Llorca, Laura Cantu Sanchez, Marat Fudim, Kevin Damman, Maria Rosa Costanzo, Beth Davison, Gad Cotter, Laurent Sandrin, Victor de Lédinghen, Alexandre Mebazaa
AimsCentral venous pressure (CVP) is an important variable in assessing heart failure (HF) patients. However, invasive CVP measurement using right heart catheterization is associated with potential complications, and accurate measurement requires careful attention to technique. In this multicentre pilot study, we aimed to evaluate whether non‐invasively measured liver stiffness can be used to assess
-
The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-16 Gabriele Fragasso, Davide Stolfo, Markus S. Anker, Antoni Bayes‐Genis, Ovidiu Chioncel, Stephane Heymans, Pardeep S. Jhund, Basil S. Lewis, Gary D. Lopaschuk, Lars H. Lund, Arantxa Gonzalez, Matteo Pagnesi, Gabriele Giacomo Schiattarella, Carlo Gabriele Tocchetti, Peter van der Meer, Sophie Von Linthout, Sven Wassmann, B. Daan Westenbrink, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese
A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation/immune activation in HF may represent an attempt to restore tissue homeostasis in the failing heart, where cardiomyocytes and immune cells undergo metabolic reprogramming
-
Reply to the letter regarding the article ‘Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-11 Nobuo Sasaki, Yukiko Nakano, Yukihito Higashi
Click on the article title to read more.
-
Reply to the letter regarding the article ‘Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-11 Yuxiang Luo, Kadir Caliskan
Click on the article title to read more.
-
Letter regarding the article ‘Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-11 Philipp Bengel, Samuel Sossalla
Click on the article title to read more.
-
Letter regarding the article ‘Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-11 Gaohua Zhang, Tong Liu, Li Huang
Click on the article title to read more.
-
Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-09 Vera Fortmeier, Amelie Hesse, Teresa Trenkwalder, Márton Tokodi, Attila Kovács, Elena Rippen, Jule Tervooren, Michelle Fett, Gerhard Harmsen, Shinsuke Yuasa, Moritz Kühlein, Héctor Alfonso Alvarez Covarrubias, Moritz von Scheidt, Ferdinand Roski, Muhammed Gerçek, Tibor Schuster, N. Patrick Mayr, Erion Xhepa, Karl‐Ludwig Laugwitz, Michael Joner, Volker Rudolph, Mark Lachmann
-
Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-09 Thibaud Damy, Rong Wang, Mathew S. Maurer, Julian D. Gillmore, Marianna Fontana
-
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-09 Riccardo M. Inciardi, Muthiah Vaduganathan, Brian Claggett, Omar F. AbouEzzeddine, Barry A. Borlaug, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Masatoshi Minamisawa, Eldrin F. Lewis, Margaret M. Redfield, Sanjiv J. Shah, Marianna Fontana, Marc A. Pfeffer, John J.V. McMurray, Scott D. Solomon
AimsThe safety and efficacy of heart failure (HF)‐directed medical therapy among patients who might be considered for further diagnostic evaluation to rule out transthyretin amyloid cardiomyopathy (ATTR‐CM) is largely unknown.Methods and resultsWe applied a previously validated ATTR‐CM screening score in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and assessed
-
Serial assessment of left ventricular ejection fraction for the management of heart failure: Unnecessary and unrealistic? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-05 Alberto Palazzuoli, Pierpaolo Pellicori, John G.F. Cleland
A recently published clinical consensus statement suggested that serial measurements of left ventricular ejection fraction (LVEF) should be done routinely for patients with heart failure, to assess disease progression and response to treatment.1 These recommendations were applied regardless of left ventricular phenotype. However, there is little evidence to suggest that serial assessment of LVEF will
-
Mechanical unloading is accompanied by reverse metabolic remodelling in the failing heart: Identification of a novel citraconate‐mediated pathway Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-04 David M. Kaye, Xiao Suo Wang, Yen Chin Koay, Mengbo Li, Bailey McIntosh, Yann Huey Ng, Michael Rahman, Yiyang Cao, Francine Z. Marques, Cassandra Malecki, Shane Nanayakarra, Justin Mariani, Bing Wang, Sean Lal, Giovanni Guglielmi, John F. O'Sullivan
AimsAlthough functional recovery of the failing heart with left ventricular assist device (LVAD) unloading can occur, the underpinning mechanism is unclear. We aimed to characterize the effect of myocardial biochemical effect of LVAD support in vivo and in vitro.Methods and resultsWe performed targeted metabolomics and lipidomics on transcardiac (arterial and coronary sinus) blood samples collected
-
Profiling hypotension in heart failure based on office, orthostatic and ambulatory blood pressure measurements Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02 Anzhela Soloveva, Darya Fedorova, Sabina Kuchinskaia, Amina Rakisheva, Victoria Galenko, Andrey Kozlenok, Svetlana Villevalde
Click on the article title to read more.
-
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02 Jan Biegus, Gracjan Iwanek, Jeffrey Testani, Robert Zymliński, Marat Fudim, Mateusz Guzik, Piotr Gajewski, Piotr Ponikowski
-
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry-based analysis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30 Guido Tavazzi, Costanza Natalia Julia Colombo, Matteo Pagnesi, Maurizio Bertaina, Andrea Montisci, Simone Frea, Marco Marini, Martina Briani, Lisa Patrini, Francesca Rossi, Letizia Bertoldi, Giulia Maj, Giovanna Viola, Carlotta Sorini Dini, Serafina Valente, Gaetano Maria De Ferrari, Nuccia Morici, Federico Pappalardo, Alice Sacco
-
Insights into the European heart failure epidemiology Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30 Petar M. Seferović, Marija Polovina, Gianluigi Savarese, Ivan Milinković, Dejana Stanisavljević, Lars Lund, Ovidiu Chioncel, Magdy Abdelhamid, Yuri Lopatin, Stefan Störk, Manuel Anguita Sanchez, Massimo Piepoli, Aldo P. Maggioni, Ewa Jankowska, Antoni Bayes‐Genis, Alain Cohen Solal, Arsen Ristić, Mariya Tokmakova, Mehmet Birhan Yilmaz, Hadi Skouri, Davor Miličić, Offer Amir, Amina Rakisheva, Gerasimos
AimsThe Heart Failure Association (HFA) of the European Society of Cardiology (ESC), together with the National Heart Failure Societies (NHFS), designed the European Heart Failure (HF) Survey with an aim of assessing contemporary HF epidemiology, management resources, availability and reimbursement of guideline‐directed medications and devices, and structure of professional and patient organizations
-
Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29 Guillaume Baudry, Guowei Li, Ruoting Wang, Rebecca A.V. Newton, Luca Monzo, Nicolas Girerd, Ana Mocumbi, Faiez Zannad, Harriette G. C. Van Spall
AimsRandomized clinical trials (RCTs) that inform international clinical practice guidelines should adequately represent regions burdened with disease. We aimed to assess the geographic representativeness of pivotal heart failure (HF) RCTs using two methodological approaches.Methods and resultsWe assessed the global geographic distribution of HF cases using the Global Burden of Disease 2021 dataset
-
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29 Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Lisa Besch, Angela Dettling, Letizia Fausta Bertoldi, Stefan Blankenberg, Jeroen Dauw, Dennis Eckner, Ingo Eitel, Tobias Graf, Patrick Horn, Joanna Jozwiak‐Nozdrzykowska, Paulus Kirchhof, Stefan Kluge, Axel Linke, Ulf Landmesser, Enzo Lüsebrink, Nicolas Majunke, Norman Mangner, Sven Möbius Winkler, Peter Nordbeck, Martin Orban, Federico Pappalardo
-
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-28 Biykem Bozkurt, Patrick Rossignol, Joseph A. Vassalotti
-
Clinical and financial implications of inpatient and outpatient management of worsening heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-27 Stephen J. Greene, Lisa A. Kaltenbach, Gregg C. Fonarow, Karen Chiswell, Veraprapas Kittipibul, Hubert B. Haywood, Muhammad Shahzeb Khan, Bradley G. Hammill, Javed Butler, Adrian F. Hernandez, G. Michael Felker
-
What's new in heart failure? May 2025 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-26 Mert Tokcan, Julian Hoevelmann, Philipp Markwirth, Bernhard Haring
Click on the article title to read more.
-
Issue Information Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-26
Click on the article title to read more.
-
Longitudinal blood pressure and cardiovascular outcomes in heart failure: An individual patient data pooling analysis of clinical trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-24 Jing‐Wei Li, Jiang Wang, Yunlong Chen, Hao Yang, Yi Wang, Xia Wang, Jingjng Xiao, Ying Wang, Dehui Qian, Shiyong Yu, Xiaohui Zhao, Hu Tan, Jun Jin, Xin Du, Craig S. Anderson
AimsPrevious analyses of the relationship between blood pressure (BP) and heart failure (HF) outcomes have primarily used baseline values rather than longitudinal measurements. We aimed to elucidate associations between longitudinal BP and clinical outcomes in patients with HF with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF)
-
Genotype‐guided cardiac device intervention in LMNA‐related cardiac conduction disorder: The need for timely genetic testing Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-24 Shunsuke Inoue, Zhehao Dai, Tsukasa Oshima, Seitaro Nomura, Takashi Hiruma, Ryo Abe, Kanna Fujita, Manami Katoh, Toshiyuki Ko, Yu Shimizu, Masamichi Ito, Kenichiro Yamagata, Junichi Ishida, Eisuke Amiya, Masaru Hatano, Norifumi Takeda, Hiroyuki Morita, Katsuhito Fujiu, Norihiko Takeda, Issei Komuro
Sudden cardiac death is a catastrophic event, making its prevention important. However, patient selection for primary prevention remains controversial. We report two cases of cardiac conduction disorder initially treated with permanent pacemaker implantation. Genetic testing later revealed novel pathogenic variants in LMNA, leading to an upgrade to implantable cardioverter‐defibrillator for primary
-
Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-22 David J. Lefer, Thomas E. Sharp, Amy L. Scarborough, Amelia G. Haydel, Sanjiv J. Shah, Zhen Li, Traci T. Goodchild
AimsOveractivity of the sympathetic nervous system is a common underlying mechanism in development and progression of several heart failure with preserved ejection fraction (HFpEF) comorbidities. Decreasing renal sympathetic nerve activity using catheter‐based renal denervation (RDN) systems have shown efficacy in treating resistant hypertension and cardiac dysfunction in heart failure with reduced
-
Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher‐ versus lower‐dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-21 Stefan D. Anker, Michele Robertson, John J.V. McMurray, Pardeep S. Jhund, Claire White, Chante Reid, Sunil Bhandari, Ken Farrington, Philip A. Kalra, Khawaja M. Talha, Patrick B. Mark, Charles R.V. Tomson, David C. Wheeler, Chris G. Winearls, Iain C. Macdougall, Ian Ford
AimsIn the PIVOTAL trial, a proactive high‐dose regimen of intravenous iron sucrose, compared to a lower‐dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and
-
DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-19 Udo Bavendiek, Nele Henrike Thomas, Dominik Berliner, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Samira Soltani, Fabian Rathje, Mircea-Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann
-
Incident heart failure is common and underrecognized in patients with biopsy‐proven metabolic dysfunction‐associated steatotic liver disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20 Kara Wegermann, Fouad Chouairi, Georgia Sofia Karachaliou, Carolyn Ahlers, Sandra Au, Kaela Miller, Tor Biering‐Sørensen, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan, Marat Fudim
-
A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20 Jerremy Weerts, Arantxa Barandiarán Aizpurua, Ravi B. Patel, Arno A. van de Bovenkamp, Hesam Amin, Sandra Sanders‐van Wijk, Sanne G.J. Mourmans, Anouk Achten, M. Louis Handoko, Antoni Bayés‐Genís, Hans‐Peter Brunner‐La Rocca, Sanjiv J. Shah, Christian Knackstedt, Vanessa P.M. van Empel
-
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20 Stephen J. Greene, Stefano Corda, Ciaran J. McMullan, Giovanni Palombo, Christina Schooss, Vanja Vlajnic, Katrin Walkamp, Michele Senni
AimsIn clinical practice, simplifying the number of medication titration steps while maintaining safety may improve the likelihood of patients with heart failure (HF) achieving target doses of guideline‐directed medical therapy (GDMT). The VELOCITY study examined whether removing the 2.5 mg initiation step for vericiguat, and instead initiating therapy at 5 mg daily, would be safe and well‐tolerated
-
Home‐based urinary sodium monitoring via point‐of‐care testing for personalized diuretic titration in heart failure management: The EASY‐STOP study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20 Evelyne Meekers, Pieter Martens, Ruben Knevels, Marie Miseur, Athanasius Ezzat, François Croset, Jeroen Dauw, Henri Gruwez, Sebastiaan Dhont, Jonas Erzeel, Marnicq Van Es, Petra Nijst, Frederik H. Verbrugge, Matthias Dupont, Stefan Janssens, Wilfried Mullens
-
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-16 Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V.
Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia. We evaluated the effects of finerenone according to anaemia status in patients
-
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-16 Jonathan W. Cunningham, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Katja Rohwedder, Laura Goea, Mario Berger, John J.V. McMurray, Scott D. Solomon
AimsN‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non‐steroidal mineralocorticoid receptor antagonist finerenone on NT‐proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is currently unknown.Methods and resultsThe FINEARTS‐HF
-
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the CardioMEMS Heart Failure System Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-14 Chris J. Kapelios, Sotiria Liori, Michael Bonios, William T. Abraham, Gerasimos Filippatos
-
Characterization of arrhythmia‐induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction – insights from DECAAF II Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-13 Ala Assaf, Han Feng, Mayana Bsoul, Ghassan Bidaoui, Hadi Younes, Christian Massad, Mario Mekhael, Charbel Noujaim, Omar Kreidieh, Swati Rao, Amitabh Pandey, Philipp Sommer, Christian Mahnkopf, Nassir Marrouche, Christian Sohns
-
Further considers on the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12 Chang Liu, Min Cao
Click on the article title to read more.
-
Reply to ‘Further considerations on the FINEARTS‐HF trial’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12 Jawad H. Butt, John J.V. McMurray
We thank the authors for acknowledging our work. The diagnosis of previously unknown diabetes and pre-diabetes was based on only one measurement of glycated haemoglobin and not at least two measurements or supplementary analyses of non-fasting glucose, fasting glucose, and oral glucose tolerance, as recommended. Therefore, it is possible that some patients might have been recategorized. However, we
-
Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12 Barbara Ponikowska, Jan Biegus
Click on the article title to read more.
-
Letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12 Chao Yang, Beibei Gao, Jinyu Huang
Click on the article title to read more.
-
Reply to ‘Assessing heart failure after surgical occlusion of the left atrial appendage’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08 Philipp Krisai, Richard P. Whitlock, Jeff S. Healey
Click on the article title to read more.
-
Assessing heart failure after surgical occlusion of the left atrial appendage. Letter regarding the article ‘Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08 Claudia Stöllberger, Josef Finsterer, Birke Schneider
Click on the article title to read more.
-
Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE‐TR registry Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08 Laura Lupi, Elena Antonioli, Angelica Praderio, Alessandro Villaschi, Elisa Soranzo, Nicola Saccani, Kamil Stankowski, Daniele Cocianni, Beniamino Pagliaro, Valeria Magni, Marco Loffi, Daniela Tomasoni, Matteo Pagnesi, Antonio Mangieri, Davide Stolfo, Gianfranco Sinagra, Marianna Adamo, Marco Metra
-
Donor heart allocation systems in Europe. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08 Hoong Sern Lim, Kevin Damman, Guillaume Baudry, Maja Cikes, Stamatis Adamopoulos, Tuvia Ben‐Gal, Nicolas Girerd, Andreas Zuckermann, Marco Masetti, Sanem Nalbantgil, Laurens Tops, Piotr Ponikowski, Maria Crespo‐Leiro, Frank Ruschitzka, Marco Metra, Finn Gustafsson
Heart transplantation remains the gold standard for treatment of most patients with advanced heart failure (HF), but despite improvements of organ recovery and utilization, donor heart scarcity remains a critically limiting factor. Detailed heart allocation systems (HASs) are in place to ensure use of organs for appropriate candidates, In Europe multiple, different HASs have evolved in different countries
-
Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-07 Gianluigi Savarese, Gabriele G. Schiattarella, Felix Lindberg, Markus S. Anker, Antoni Bayes‐Genis, Magnus Bäck, Frieder Braunschweig, Chiara Bucciarelli‐Ducci, Javed Butler, Antonio Cannata, Federico Capone, Ovidiu Chioncel, Emilia D'Elia, Arantxa González, Gerasimos Filippatos, Nicolas Girerd, Jean‐Sébastien Hulot, Carolyn S.P. Lam, Lars H. Lund, Christoph Maack, Brenda Moura, Mark C. Petrie, Massimo
Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with
-
Residual tricuspid regurgitation after tricuspid valve interventions: What do we know? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-06 Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg Hausleiter
Introduction Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.1 Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge
-
Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05 Ovidiu Chioncel, Alexandre Mebazaa, Dimitrios Farmakis, Magdy Abdelhamid, Lars H. Lund, Veli‐Pekka Harjola, Stefan Anker, Gerasimos Filippatos, Tuvia Ben‐Gal, Kevin Damman, Hadi Skouri, Laura Antohi, Sean P. Collins, Marianna Adamo, Oscar Miro, Loreena Hill, John Parissis, Brenda Moura, Christian Mueller, Ewa Jankowska, Yury Lopatin, Mark Dunlap, Maurizio Volterrani, Marat Fudim, Andreas J. Flammer
-
Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05 Melanie Paillard, Mahmoud Abdellatif, Ioanna Andreadou, Christian Bär, Luc Bertrand, Bianca J.J.M. Brundel, Gemma Chiva‐Blanch, Sean M. Davidson, Dana Dawson, Fabio Di Lisa, Paul Evans, Zoltan Giricz, Derek J. Hausenloy, Petra Kleinbongard, Frank Lezoualc'h, Elisa Liehn, Christoph Maack, Ange Maguy, Elizabeth Murphy, Cinzia Perrino, Maurizio Pesce, Peter P. Rainer, Katrin Streckfuss‐Bömeke, Matthias
-
Video thermography uncovers relationship between volume status and temperature in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05 Pawel Rubiś, Adam Piórkowski, Mateusz Winiarczyk, Karolina Nurzyńska, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Mariusz Marzec, Julia Lasek, John G.F. Cleland, Piotr Augustyniak
AimsThermoregulation is a fundamental aspect of mammalian homeostasis. Skin blood flow has a key role to play in thermoregulation. Heart failure (HF) can disrupt thermoregulation. Infrared thermography (IRT) offers a non‐invasive method to map skin temperature (Ts). The aim of this study was to investigate the relationships between IRT‐assessed thermoregulation, circulatory volume, and exercise in
-
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-04 Nobuo Sasaki, Yoshitaka Ueno, Ryoji Ozono, Yukiko Nakano, Yukihito Higashi
-
Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-02 Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff
-
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-30 Stefan D. Anker, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine Deheer, Meike Rybczynski, Antoni Bayes‐Genis, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J. Pinto, Tienush Rassaf, Maurizio
-
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-30 Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay‐Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern‐En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon
-
Integrated role of cardiac magnetic resonance and genetics in predicting left ventricular reverse remodelling in dilated and non‐dilated cardiomyopathy Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-29 Martina Setti, Manuela Iseppi, Job A.J. Verdonschot, Jacopo G. Rizzi, Alessia Paldino, Carola Pio Loco Detto Gava, Giulia Barbati, Matteo Dal Ferro, Max F.G.H.M. Venner, Anne G. Raafs, Marta Gigli, Davide Stolfo, Antonio De Luca, Giulia De Angelis, Teresa M. Capovilla, Sharon Graw, Flavio L. Ribichini, Matthew Taylor, Luisa Mestroni, Stephane R.B. Heymans, Gianfranco Sinagra, Marco Merlo
-
Issue Information Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27
Click on the article title to read more.
-
What's new in heart failure? April 2025 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27 Alberto Aimo, Pau Codina, Matthew M.Y. Lee, Daniela Tomasoni, Michael Böhm
Click on the article title to read more.
-
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27 Antoni Bayes‐Genis, Matteo Pagnesi, Pau Codina, William T. Abraham, Offer Amir, Rudolf A. de Boer, Jasper J. Brugts, Ovidiu Chioncel, Finn Gustafsson, JoAnn Lindenfeld, Wilfried Mullens, Mark C. Petrie, Giuseppe Rosano, Marco Metra
Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early haemodynamic changes so that medical therapy can be adjusted